Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2025-11-14
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
$3.4bn
reported value
+44.3% vs Q2 2025
33positions
68.0%in top 10
10 new
13 added
7 reduced
5 sold out
vs Q2 2025
Options: 2 call positions ($36.3m notional), 1 put positions ($100.2m notional) – listed below, not included above.
Holdings, Q3 2025
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| NUVALENT INC COM | $455.7m13.48% | Unchanged |
| MERUS N V MRUS | $411.8m12.18% | Added +91.8k |
| ARCELLX INC ACLX | $381.7m11.29% | Unchanged |
| REVOLUTION MEDICINES INC RVMD | $290.6m8.60% | Added +130.0k |
| TARSUS PHARMACEUTICALS INC TARS | $158.4m4.69% | Reduced -310.4k |
| VAXCYTE INC PCVX | $136.3m4.03% | Added +411.9k |
| ABIVAX SA ABVX | $132.8m3.93% | New |
| GENMAB A/S GMAB | $117.1m3.46% | New |
| AGIOS PHARMACEUTICALS INC AGIO | $107.3m3.18% | Added +1.5m |
| CRINETICS PHARMACEUTICALS IN CRNX | $106.2m3.14% | Added +207.2k |
| EDGEWISE THERAPEUTICS INC EWTX | $100.1m2.96% | Added +27.8k |
| CIDARA THERAPEUTICS INC CDTX | $92.0m2.72% | New |
| UROGEN PHARMA LTD URGN | $84.1m2.49% | New |
| SCHOLAR ROCK HLDG CORP SRRK | $74.8m2.21% | Added +409.2k |
| JANUX THERAPEUTICS INC JANX | $71.4m2.11% | Unchanged |
| OLEMA PHARMACEUTICALS INC OLMA | $66.5m1.97% | Added +30.0k |
| APOGEE THERAPEUTICS INC COM | $60.5m1.79% | Added +563.1k |
| VIRIDIAN THERAPEUTICS INC VRDN | $56.3m1.67% | Reduced -132.2k |
| ALKERMES PLC ALKS | $51.6m1.53% | Added +343.8k |
| LENZ THERAPEUTICS INC LENZ | $50.0m1.48% | Reduced -643.6k |
| PHARVARIS N V PHVS | $45.8m1.36% | Added +772.6k |
| COGENT BIOSCIENCES INC COGT | $45.3m1.34% | Reduced -7.2m |
| OCULAR THERAPEUTIX INC OCUL | $40.9m1.21% | Added +77.0k |
| BRIDGEBIO PHARMA INC BBIO | $35.5m1.05% | Reduced -281.5k |
| ERASCA INC ERAS | $29.6m0.87% | Added +1.7m |
| EYEPOINT PHARMACEUTICALS INC EYPT | $28.6m0.84% | New |
| TANGO THERAPEUTICS INC TNGX | $25.9m0.77% | New |
| AMYLYX PHARMACEUTICALS INC AMLX | $25.8m0.76% | New |
| SPYRE THERAPEUTICS INC SYRE | $24.6m0.73% | Reduced -403.2k |
| DYNE THERAPEUTICS INC DYN | $24.0m0.71% | New |
| BRIDGEBIO ONCOLOGY THERAPEUT BBOT | $21.6m0.64% | New |
| DISC MEDICINE INC IRON | $16.4m0.48% | Reduced -963.3k |
| STRUCTURE THERAPEUTICS INC GPCR | $10.4m0.31% | New |
Sold out since Q2 2025
| Security | Value then |
|---|---|
| BEIGENE LTD ONC | $84.2m347.8k shares |
| MOONLAKE IMMUNOTHERAPEUTICS MLTX | $41.5m878.3k shares |
| Y-MABS THERAPEUTICS INC YMAB | $19.1m4.2m shares |
| IMMATICS N.V IMTX | $16.9m3.1m shares |
| CRESCENT BIOPHARMA INC. CBIO | $10.4m642.7k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| SPDR SER TR XBI · Put | $100.2m1.0m shares | New |
| MERUS N V MRUS · Call | $28.2m300.0k shares | New |
| AGIOS PHARMACEUTICALS INC AGIO · Call | $8.0m200.0k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |